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doi:10.1Objective: We explored effects of nonselective cyclooxygenase and selective cyclooxygenase 2 inhibition on
collateral development in a model of chronic myocardial ischemia. We hypothesized that cyclooxygenase 2 in-
hibitors would negatively effect angiogenic and inflammatory pathways.
Methods:Yorkshire swine were made chronically ischemic by placing an ameroid constrictor on the left circum-
flex coronary artery. Swine were divided into 3 groups and given no drug (control, n ¼ 7), a nonselective cyclo-
oxygenase inhibitor (naproxen 400 mg daily, n¼ 7), or a selective cyclooxygenase 2 inhibitor (celecoxib 200 mg
daily, n ¼ 7). After 7 weeks, coronary angiography was performed. Myocardial function and microvascular
reactivity were assessed. Serum and myocardial tissue were analyzed for prostaglandin levels and markers of
inflammation and angiogenesis.
Results: The celecoxib group demonstrated significantly increased mean arterial pressure and decreased left ven-
tricular function. Myocardial perfusion in the celecoxib group was similar to control value but less than in the
naproxen group. Coronary microvascular contraction in the collateral-dependent territory was increased in the
naproxen group but minimally affected in the celecoxib group. Oxidative stress and apoptosis were increased
in the celecoxib group. Expression of angiogenic markers vascular endothelial growth factor and phospho–endo-
thelial nitric oxide synthase (ser1177) and tissue levels of prostacyclin were decreased in both celecoxib and
naproxen groups. The naproxen group had diminished endostatin expression.
Conclusions: Selective and nonselective cyclooxygenase inhibition are more complex in effect than previously
published, but they did not decrease collateral-dependent blood flow to the myocardium in our model of chronic
myocardial ischemia. (J Thorac Cardiovasc Surg 2010;140:1143-52)Selective inhibitors of the inducible isoform of cyclooxyge-
nase (COX-2) were developed to provide relief of pain
associated with arthritis, surgery, and other conditions while
lowering the incidence of gastrointestinal complications
relative to nonselective nonsteroidal anti-inflammatory
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Spurported, however, to increase the risk of adverse cardio-
vascular events, such as myocardial infarction, and to in-
crease mortality. One widely prescribed selective COX-2
inhibitor, rofecoxib, was removed from the market in 2004
because of an increased incidence of adverse cardiovascular
events observed during the VIGOR trial, which examined
the effects of rofecoxib on arthritic pain relief.2 On the other
hand, nonselective NSAIDs have also been implicated in
increased cardiovascular events.3,4 As a consequence, both
selective and nonselective NSAID COX inhibitors carry
a ‘‘black box warning’’ from the United States Food and
Drug Administration related to the perceived risk of
increased cardiovascular events.
COX is responsible for the production of thromboxane
(TX) A2 in platelets, which facilitates thrombosis and is a va-
soconstrictor in most vascular beds. TXA2 is antagonized by
low-dose aspirin. On the other hand, in endothelium COX
catalyzes the formation of prostacyclin (PGI2), a substance
known to be an antithrombotic and a vasodilator. In the
so-called FitzGerald hypothesis, the key to potential cardio-
vascular side effects with selective COX-2 inhibitors was
purported to be related to the balance between the prothrom-
botic and antithrombotic prostaglandins. In 2006, FitzGer-
ald5 published a mouse study in which selective inhibition
by knockout of COX-2 or deletion of the PGI2 receptor
yielded an increase in thrombotic events and elevated blooddiovascular Surgery c Volume 140, Number 5 1143
Abbreviations and Acronyms
ADP ¼ adenosine diphosphate
COX ¼ cyclooxygenase
JNK ¼ c-Jun N-terminal kinase
LCx ¼ left circumflex coronary artery
NSAID ¼ nonsteroidal anti-inflammatory drug
PGF1a ¼ prostaglandin F1a
PGI2 ¼ prostacyclin
TX ¼ thromboxane
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Spressure. Inhibition of COX-1, which simulates the effects
of aspirin, reversed these effects.
Another theory consistent with increased cardiovascular
risk from long-term selective COX-2 inhibition was pro-
posed by Wu and associates.6 In their study, inhibition of
COX-2 in cell culture led to decreased angiogenesis. In
addition, the formation of vascular structures in Matrigel
(BD Biosciences, San Jose, Calif) was accelerated in
COX-2–overexpressing cells but attenuated in cells trans-
fected with COX-2 small inhibitory RNA. This finding sug-
gests that selective COX-2 inhibitors may lead to decreased
angiogenesis and coronary collateral formation. With fewer
(or less well developed) protective collateral vessels, pa-
tients may suffer more devastating outcomes during ische-
mic cardiac events. Coronary collateral development has
been associated with reduced risks of death and myocardial
injury after coronary artery occlusion.7
At this time, no studies have examined the effects of non-
selective COX or selective COX-2 inhibitors on angiogene-
sis or myocardial perfusion in any large animal model of
chronic myocardial ischemia. We hypothesized that inhibi-
tion of COX-2 would alter the productions of TXA2 and
PGI2, negatively effect coronary collateral formation and
proangiogenic pathways, and lead to diminished collateral-
dependent myocardial perfusion.
METHODS
Study Design
Yorkshire miniswine (Parsons Research, Amherst, Mass) were divided
into 3 groups. One group received celecoxib at 200 mg orally per day
(n ¼ 8), another received naproxen at 400 mg orally per day (n ¼ 10),
and the third received no drug (control, n ¼ 8). All animals received drug
treatment for 7 weeks, beginning at the time of ameroid placement. All an-
imals underwent ameroid constrictor placement on the proximal left circum-
flex coronary artery (LCx). For all surgical procedures, anesthesia was
induced with ketamine hydrochloride (10 mg/kg intramuscularly) and thio-
pental sodium (2.5%) and maintained with a gas mixture of oxygen at 1.5 to
2 L/min and 3.0% isoflurane. The animals were intubated and mechanically
ventilated at 16 breaths/min. During the first procedure, the pericardiumwas
opened through a left minithoracotomy, and a titanium ameroid constrictor
(1.75-mm internal diameter; Research Instruments SW, Escondido, Calif)
was placed around the proximal LCx. Seven weeks after ameroid
placement, each swine was again anesthetized, the heart was exposed,
and physiologic measurements were taken, followed by humane killing.1144 The Journal of Thoracic and Cardiovascular SurThe swine were not given any medication to prevent or treat potential
arrhythmias.
Once the heart had been removed, myocardial samples were rapidly
frozen in liquid nitrogen for molecular studies, placed in 4CKrebs solution
for microvessel reactivity studies, or placed in 10% formalin for immuno-
histochemical studies.
All experiments were approved by the Beth Israel Deaconess Medical
Center institutional animal care and use committee. Animals were cared
for in compliance with the Harvard Medical Area institutional animal care
and use committee and in accordance with the Principles of Laboratory An-
imal Care formulated by the National Society for Medical Research and the
Guide for the Care and Use of Laboratory Animals (www.nap.edu/catalog/
5140.html).
Measurement of Global and Regional Myocardial
Function
Indices of global and regional left ventricular function were measured
before animals were killed and included the following: systolic blood pres-
sure, developed left ventricular pressure, positive and negative first deriva-
tives of left ventricular pressure, and longitudinal and horizontal segmental
shortening in the area at risk for 10 sequential beats, as determined with
a Sonometrics system (Sonometrics Corp, London, Ontario, Canada).
X-Ray Coronary Angiography
X-ray coronary angiography with iohexol (Omnipaque; GE Healthcare,
Princeton, NJ) was carried out to ensure occlusion of the LCx and to assess
collateral formation. Recorded images were interpreted by an interventional
cardiologist (R.J.L.) blinded to the treatment groups. Angiographic collat-
eral formation was assessed according to the blush score and Rentrop grad-
ing system, depending on the presence and extension of the collateral filling
of coronary epicardial vessels.
Microvessel Studies
After cardiac removal, coronary arterioles (80–180 mm in diameter) from
the ischemic territory were dissected from the surrounding tissue and placed
in an isolated microvessel chamber as described previously.8 After precon-
traction of microvessels by 30% to 50% of the baseline diameter with the
TXA2 analog U46619 (0.1–1.0 mmol/L), the microvascular responses to
vasorelaxing agents sodium nitroprusside (109 to 104 mol/L, an
endothelium-independent cyclic guanosine monophosphate–mediated
vasodilator) and adenosine diphosphate (ADP, 109–104 mol/L, an
endothelium-dependent vasodilator) were evaluated. Responses to vasocon-
stricting agents endothelin 1 (1012–107) and serotonin (109–105) were
assessed in vessels that had not been precontracted. All drugs were applied
extraluminally. Responses were defined as percentage relaxation of the pre-
constricted diameter for ADP and sodium nitroprusside and as percentage
constriction of baseline diameter for endothelin 1 and serotonin. All
reagents were obtained from Sigma-Aldrich (St Louis, Mo).
Myocardial Perfusion Analysis
Myocardial perfusionwas determined with isotope-labeledmicrospheres
15 mm in diameter (BioPAL Worcester, Mass) according to previously re-
ported methods.9 Briefly, 1.5 3 107 gold-labeled microspheres were in-
jected during temporary LCx occlusion at the time of ameroid placement
to identify the area at risk. Lutetium (rest conditions) and europium (ventric-
ular pacing at 150 beats/min) isotopically labeled microspheres were
injected before the animal was killed. After the animal was killed, left ven-
tricular sections were collected for isotope-labeled microsphere assay. The
samples were exposed to neutron beams, and microsphere densities were
measured with a gamma counter.
Immunoblotting Studies
Tissue lysate was made from the ischemic myocardium. A 60-mg sample
of total protein was fractionated by 4% to 20% gradient sodium dodecylgery c November 2010
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Ssulfate polyacrylamide gel electrophoresis (Invitrogen Corporation, Carls-
bad, Calif) and transferred to polyvinylidene fluoride membranes (Milli-
pore, Billerica, Mass). Each membrane was incubated with specific
primary antibodies. Antibodies were obtained from Cell Signaling (Cell
Signaling Technology, Inc, Danvers, Mass), BD Biosciences, and Abcam
(Abcam Inc, Cambridge, Mass). Immune complexes were visualized with
the enhanced chemiluminescence detection system (Amersham, Piscat-
away, NJ). Bands were quantified by densitometric evaluation of autoradio-
graph films. Ponceau staining was used to ensure equal protein loading.
Immunofluorescence Double Staining for Dividing
and Total Endothelial Cells
Frozen sections (12 mm in thickness) of myocardium from the ischemic
territories were formalin fixed. Antibodies against proliferation marker Ki-
67 (Abcam) and PECAM-1 (CD-31; R&D Systems, Inc, Minneapolis,
Minn) were simultaneously applied to the sections and incubated. Detection
was obtained with appropriate secondary antibodies (Jackson ImmunoRe-
search Laboratories, Inc, West Grove, Pa). Sections were mounted in Vec-
tashield with 40,6-diamidino-2-phenylindole (Vector Laboratories, Inc,
Burlingame, Calif). Photomicrographs were taken with a Zeiss Axiolab mi-
croscope (Carl Zeiss, Inc, Thornwood, NY) equipped with a digital camera
at 2003 magnification (PhotoDoc-It; UVP, LLC, Upland, Calif). Total and
dividing endothelial cells were counted in a blinded fashion. Data are pre-
sented as numbers of Ki-67–positive endothelial cells per square millimeter.
Tissue TX and Tissue and Serum PGI2 Levels
Tissue levels of stable TX and PGI2 breakdown products, 11-dehydro-
TXB2 and 6-keto prostaglandin F1a (PGF1a), respectively, were measured
by enzyme-linked immunosorbent assay (Neogen Corp, Lexington, Ky).
Tissue lysates from the ischemic myocardium underwent liquid–liquid
exchange, extraction, and concentration according to the manufacturer’s
recommendations. The samples were put into an antibody-coated plate
along with horseradish peroxidase–conjugated 6-keto PGF1a. The plate
was washed, and horseradish peroxidase substrate was added. The plate
was incubated and then read at 650 nm, and sample results were plotted
against the standard curve.
Serum levels of 6-keto PGF1a were measured by enzyme-linked immu-
nosorbent assay (Neogen). Serum samples underwent liquid–liquid
exchange, extraction, concentration, and assay as described previously.
Myocardial Protein Oxidative Stress
Dinitrophenylhydrazine-derivatized myocardial tissue homogenates
were separated by 10% polyacrylamide gel electrophoresis and transferred
to polyvinylidene fluoride membranes (Chemicon International, Inc, Teme-
cula, Calif). The membranes were incubated with primary antibody specific
to dinitrophenylhydrazine, followed by incubation with a horseradish
peroxidase-linked secondary antibody. Immune complexes were visualized
with the enhanced chemiluminescence detection system (Amersham).
Myocardial Lipid Oxidative Stress
Measurement of lipid peroxidation in the ischemic myocardium was car-
ried out with a commercial kit to assess levels of free malondialdehyde, a re-
active carbonyl compound produced during decomposition of lipid peroxides
(Oxis International Inc, FosterCity,Calif). Homogenateswere incubatedwith
N-methyl-2-phenylindole in acetonitrile, probucol, and concentrated hydro-
chloric acid. Samples were centrifuged, and the malondialdehyde-
containing supernatant was removed. Absorbance was measured at 586 nm,
and values were analyzed against a standard curve. Levels of malondialde-
hyde were corrected for protein concentration differences between samples.
Quantification of Apoptotic Cells
Apoptotic cells in the myocardium were identified with the ApopTag
detection kit according to manufacturer’s specifications (Millipore). At leastThe Journal of Thoracic and Car1 cm2 of tissue was analyzed from each animal (4 per group). The number of
cardiomyocytes found to be positive by terminal deoxynucleotidyl transfer-
ase–mediated deoxyuridine triphosphate nick end labeling was expressed as
positive cells per square centimeter.
Data Analysis
All results are expressed as mean SEM.Microvessel responses are ex-
pressed as percentage relaxation of the preconstricted diameter or as con-
traction of the baseline diameter and were analyzed with 2-way repeated
measures analysis of variance with a post hoc Bonferroni test, which was
applied to interactions of treatment and dose. Western blots were analyzed
after digitization (ScanJet 4c; Hewlett-Packard Company, Palo Alto, Calif)
with NIH ImageJ 1.33 software (National Institutes of Health, Bethesda,
Md). For data analysis, levels of phosphorylated proteins were normalized
to total expression levels. Comparisons among the 3 groups were analyzed
by 1-way repeated measures analysis of variance with Newman–Keuls mul-
tiple comparison post hoc test by means of GraphPad Prism 4 (GraphPad
Software, Inc., La Jolla, Calif).
RESULTS
Animal Model
During the course of this study, there were 5 deaths: 1 in
the control group, 1 in the celecoxib group, and 3 in the nap-
roxen group. The animals that died in the naproxen and cel-
ecoxib groups showed symptoms consistent with heart
failure, tachypnea, and abdominal ascites. These animals
died an average of 32  1.2 days after ameroid placement.
There were 7 animals included in each group for analysis af-
ter 2 replacement animals were added to the naproxen group.
Functional Data
Heart rate was significantly lower in the celecoxib group
than in the control group (control 138  17 beats/min, nap-
roxen 108  17 beats/min, and celecoxib 90  4 beats/min,
P ¼ .04). Both mean arterial pressure and left ventricular
pressure were significantly higher in the celecoxib group.
In addition, segmental shortening was significantly higher
in the celecoxib group than in the control and naproxen
groups. The positive first derivative of left ventricular pres-
sure over time, a preload- and afterload-independent mea-
sure of global left ventricular function, was lower in the
celecoxib group than in the naproxen and control groups
(Figure 1, A–D).
Collateral–Dependent Blood Flow in the Ischemic
Territory
There was a significant increase in absolute blood flow
at rest in the naproxen group. In all groups, absolute blood
flow was unaffected by ventricular pacing (150 beats/
minute; Figure 2, A and B). Collateral-dependent myocar-
dial blood flows were similar in the celecoxib and control
groups at rest and with pacing. There were no differences
in left anterior descending coronary arterial flow among
the groups at rest (control 0.86  0.17 mL/[min $ g],
naproxen 1.22  0.18 mL/[min $ g], and celecoxib
1.00  0.18 mL/[min $ g], P ¼.36) or during paced
conditions (control 0.96  0.13 mL/[min $ g], naproxendiovascular Surgery c Volume 140, Number 5 1145
FIGURE 1. Myocardial functional data. A, Mean arterial blood pressure (MAP) is increased in celecoxib (CBX) group (asterisk indicates P<.001). B, Left
ventricular pressure (LVP) is increased in celecoxib group (dagger indicates P¼ .004). C, Vertical segmental shortening (VSS) is increased in celecoxib group
(double dagger indicates P¼ .02). D, Positive first derivative of developed pressure over time (þdP/dt) is decreased in celecoxib group (section mark indicates
P ¼ .04). NAP, Naproxen.
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0.18 mL/[min $ g], P ¼ .83).
Coronary Angiography
In all cases, total LCx occlusion was observed during the
final coronary angiogram, and there were no differences in
observed Rentrop scores (control 0.89  0.3, naproxen
1.4  0.38, and celecoxib 1.6  0.37, P ¼ .35). There
were also no differences in observed blush scores among
the groups (control 0.17  0.17, naproxen 0.8  0.37, and
celecoxib 0.5  0.22, P ¼ .25).
Microvascular Function
Therewere no differences in baselinemicrovessel diameter
among groups (control 156 13mm, naproxen 140 10mm,FIGURE 2. Blood flow in collateral-dependent territory. A, Blood flow to isch
dicates P ¼ .03. B, There is significantly increased blood flow to ischemic territo
1146 The Journal of Thoracic and Cardiovascular Surand celecoxib 142  10 mm, P ¼ .60). Likewise, there were
no differences among groups in the preconstricted diameter
(control 96  5 mm, naproxen 86  13 mm, celecoxib 94 
7 mm, P ¼ .78) or percentage precontraction (control
36.6%  2%, naproxen 36.0%  3.1%, celecoxib
34.1%  1.4%, P ¼ .73) of microvessels. There was
a greater contraction response in the naproxen group to
endothelin-1 than in the control and celecoxib groups.
Serotonin-induced contraction was greater in the naproxen
group than in both control and celecoxib groups.When exam-
ining the microvascular response to ADP, an endothelium-
dependent vasorelaxing agent, the celecoxib group demon-
strated decreased relaxation response at the highest dose of
ADP relative to the control and naproxen groups. There
were no differences among groups when the vessels wereemic myocardium at rest is increased in naproxen (NAP) group (asterisk in-
ry during ventricular pacing in naproxen group (dagger indicates P ¼ .02).
gery c November 2010
FIGURE 3. Microvascular responses. A, Microvessel responses to endothelin-1 (ET-1) demonstrate significantly increased contractions in naproxen (NAP)
group at 108 (asterisk indicates P ¼ .001 vs control and celecoxib [CBX]) and 109 (dagger indicates P ¼ .001 vs control). Percentage contraction is not
different between control and celecoxib groups at any concentration. B, Contraction responses to serotonin demonstrate increases in naproxen group at
106 (double dagger indicates P¼ .001 vs control and celecoxib) and 105 (section mark indicates P¼ .04 vs control). C, Relaxation responses to adenosine
diphosphate (ADP), endothelium-dependent vasorelaxation agent, show decreasedmicrovascular responses in celecoxib group (parallel lines indicateP¼ .01
vs control and naproxen). D, Responses to sodium nitroprusside (SNP) are not different among groups (P ¼ .22).
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Ssubjected to sodium nitroprusside, an endothelium-
independent vasorelaxing agent (Figure 3, A–D).
Levels of PGI2 and TX in the Ischemic Myocardium
and Serum
The naproxen group exhibited a marked decrease in tissue
levels of PGF1a, whereas PGF1a in the celecoxib group was
slightly reduced relative to control. The naproxen and cele-
coxib groups both had markedly lower serum levels of
PGF1a than did the control group. Both the naproxen and
celecoxib groups demonstrated a trend toward increased tis-
sue levels of TXB2, although these differences did not reach
statistical significance (Figure 4, A–C).
Levels of Tissue Oxidant Stress
The celecoxib group demonstrated significantly higher
levels of protein oxidative stress in the ischemic territory
of the left ventricle (Figure 5, A). Levels of tissue malondial-
dehyde (lipid oxidative stress) were similar among the
groups (Figure 5, B).
Quantification of Capillary Growth and Density
Both the naproxen and celecoxib groups demonstrated
fewer dividing endothelial cells than did the control group.
In the assessment of the total number of endothelial cells
in the ischemic myocardium, there were also significantly
fewer cells in the naproxen and celecoxib groups than in
the control group (Figure 6, A–E).The Journal of Thoracic and CarLevels of Apoptosis
The number of apoptotic cells in the ischemic myocar-
dium in the celecoxib group was significantly increased
relative to the control and naproxen groups (control
0.017  0.002 cells/cm2, naproxen 0.050  0.023 cells/
cm2, celecoxib 0.092  0.047 cells/cm2, P ¼ .002).
Immunoblotting
In the examination of proangiogenic proteins, vascular
endothelial growth factor and vascular endothelial growth
factor receptor 2 expressions were decreased in the ischemic
myocardium of both naproxen and celecoxib groups relative
to the control group. Similarly, expressions of phospho–en-
dothelial nitric oxide synthase (ser1177) were diminished in
both naproxen and celecoxib groups. Expression of c-Jun N-
terminal kinase (JNK) was increased in the celecoxib group
relative to the control group. Expression of the antiangio-
genic protein endostatin was significantly lower in the nap-
roxen group than in the control and celecoxib groups
(Figure 7, A–E). Expressions of phospho-Akt (ser473)
were increased 1.4-fold in the naproxen and celecoxib
groups, but this did not reach significance (P ¼ .10). There
was also a trend toward increased tumor necrosis factor a ex-
pression in the celecoxib group relative to the control and
naproxen groups (P ¼ .08). There were no differences
among the groups in the myocardial expression levels of
nuclear factor kB (P ¼ .11), extracellular signal–regulated
kinase (P ¼ .76), or apoptosis-inducing factor (P ¼ 0.55).diovascular Surgery c Volume 140, Number 5 1147
FIGURE 4. Serum and tissue levels of prostaglandins and thromboxane. A, Tissue levels of prostaglandin F1a (PGF1) show marked decrease in naproxen
(NAP) group (asterisk indicates P<.001 vs control and celecoxib) and significant decrease in celecoxib group as well (dagger indicates P<.05 vs control). B,
Serum prostaglandin (PGI1a) levels are significantly higher in control group (double dagger indicates P¼ .004 vs naproxen and celecoxib). C, Tissue levels of
thromboxane B2 (TXB2) are slightly increased in naproxen and celecoxib groups (P ¼ .25 vs control).
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SDISCUSSION
The principle findings of this study are that the nonselec-
tive COX inhibitor naproxen increased collateral-dependent
perfusion in a chronic model of myocardial ischemia relative
to untreated animals, whereas the selective COX-2 inhibitor
celecoxib did not alter collateral-dependent perfusion. Se-
rum levels of PGI2 were reduced to a similar extent by
both drugs, and tissue levels of TXA2 were slightly and
similarly increased relative to untreated animals. Capillary
densities in the collateral-dependent myocardium were
diminished in both naproxen and celecoxib groups.
Previous studies have demonstrated that both nonselec-
tive COX10 and selective COX-2 inhibitors11 diminish
coronary collateral perfusion. Most previous studies haveFIGURE 5. Levels of protein and lipid oxidative stress (Ox Stress) in normal an
are increased in celecoxib (CBX) group (asterisk indicates P¼ .001 vs control an
in ischemic territory in naproxen group (P ¼ .07). MDA, Malondialdehyde.
1148 The Journal of Thoracic and Cardiovascular Surexamined the effects of indomethacin and other nonspecific
COX inhibitors on acute collateral-dependent perfusion or
regulation of vasomotor tone, rather than their chronic ef-
fects on collateral development.12 In our study, we treated
pigs with either naproxen or celecoxib for 7 weeks. Blood
flow to the collateral-dependent region was increased with
nonselective COX inhibition, although there was no increase
in vessel density or in the level of vasodilatory proteins.
There was no difference among the groups with regard to
the microvessel responses to sodium nitroprusside, an
endothelium-independent vasorelaxation agent. The cele-
coxib group did, however, demonstrate slightly decreased
relaxation responses to ADP, an endothelium-dependent
vasorelaxation agent. The etiology of improved perfusiond ischemic myocardium. A, Protein peroxidation levels in ischemic territory
d naproxen [NAP]). B, There is trend toward decreased lipid oxidative stress
gery c November 2010
FIGURE 6. Quantification of dividing and total endothelial cells. Double staining for endothelium (CD-31, green) and dividing cells (Ki-67, red) with
40,6-diamidino-2-phenylindole (blue) allows visualization of dividing endothelial cells in ischemic territory, which appear pink in combined image. A, In
this representative section for control group, there are many dividing endothelial cells. B, Representative myocardial section from ischemic area of naproxen
group demonstrates fewer dividing endothelial cells. C, Representative image from celecoxib group. All images taken at 2003 magnification. D, Quantifi-
cation of Ki-67–positive endothelial cells demonstrates significant increases in control group relative to naproxen (NAP) and celecoxib (CBX) groups (asterisk
indicates P ¼ .003). There is no difference between naproxen and celecoxib groups. E, Similarly, total number of endothelial cells in ischemic territory is
significantly lower in naproxen and celecoxib groups than in control (dagger indicates P ¼ .003).
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Sto the ischemic territory in the naproxen group is not clear
but may be related to preserved microvascular relaxation
and withdrawal of a vasoconstrictor effect of COX inhibi-
tion. Endostatin, a powerful endogenous inhibitor of angio-
genesis, has been shown to reduce blood flow locally.13
Thus it is possible that the lower expression of endostatin
in the ischemic territory of the naproxen group contributed
to improved blood flow.
The celecoxib group demonstrated significantly increased
mean arterial and left ventricular developed pressures, as
well as worsened global left ventricular function relative to
the other groups. Nearly all NSAIDs are associated with
the development of systemic hypertension.14 Causes of in-The Journal of Thoracic and Carcreased blood pressure may include sodium retention,15
decreased prostaglandin concentrations,16 and renal vaso-
constriction related to local enothelin-1 production.17 In
our study, naproxen was not associated with hypertension.
It is unclear why animals in the celecoxib group had lower
heart rates than those in the control group. We did not assess
stroke volume or cardiac output, because the change in heart
rate may have been compensatory for other hemodynamic
changes.
The role of COX-2 as a proangiogenic factor has been
well described.18 Both nonselective COX and selective
COX-2 inhibition led to significantly decreased endothelial
density and proliferation. Both drugs caused downregulationdiovascular Surgery c Volume 140, Number 5 1149
FIGURE 7. Immunoblotting in ischemic myocardium. A, Levels of vascular endothelial growth factor (VEGF) are highest in control group and decreased in
naproxen (NAP) and celecoxib (CBX) groups (asterisk indicates P ¼ .001 vs naproxen and celecoxib). B, Expression of phospho–endothelial nitric oxide
synthase (p-eNOS) is highest in control group (dagger indicates P ¼ .002 vs naproxen and celecoxib). C, Vascular endothelial growth factor receptor 2
(VEGFR2) is likewise downregulated in naproxen and celecoxib groups (double dagger indicates P ¼ .04 vs naproxen and celecoxib). D, c-Jun N-terminal
kinase (JNK) expression level is increased in celecoxib group (section mark indicates P ¼ .04 vs control). There is no significant difference between control
and naproxen groups. E, Endostatin, antiangiogenic protein, is significantly downregulated in naproxen group relative to control and celecoxib groups (par-
allel lines indicate P ¼ .02). Post hoc analysis revealed no difference between control and celecoxib groups.
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growth factor receptor 2, and phospho–endothelial nitric ox-
ide synthase, essential components of the angiogenic path-
way. The decrease in endostatin in the naproxen group
was unexpected. A decrease in this protein might have re-
sulted in increased collateral formation, but in this case it
did not, at least at the capillary level. There may have also
been other unmeasured antiangiogenic proteins, such as
angiostatin and tumastatin, in the drug-treated groups.
Surprisingly, this reduction in expression of proangiogenic
mediators was not associated with a reduction in
collateral-dependent perfusion. Blood flow to the myocar-1150 The Journal of Thoracic and Cardiovascular Surdium is controlled by numerous vasoactive substances and
autoregulation, which may have influenced the results.
Interestingly, we did observe an increase in expression of
the proapoptotic protein JNK in the ischemic myocardium
of the animals in the celecoxib group. Levels of apoptosis
at the time the animals were killed were increased in the cel-
ecoxib group, and this may have been mediated in part by
JNK signaling. It has been reported that JNK leads to apo-
ptosis through Lkb1.19 JNK has been shown to be activated
by increased levels of oxidative stress.20 We did not see
upregulation of apoptosis-inducing factor, another protein
involved with apoptosis.gery c November 2010
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were found in the ischemic myocardium of animals in the
celecoxib group but not the naproxen group. Previous stud-
ies have demonstrated increases in reactive oxygen species
and oxidative stress with some but not all COX-2 inhibitors,
and this is thought to result in higher rates of apoptosis.21 In-
creased levels of oxidant stress have been linked to left ven-
tricular remodeling and the development of heart failure.22
Although most NSAIDs have been implicated in increasing
oxidant stress, we did not observe this in the myocardium at
the dose of naproxen used in this model.
The first selective COX-2 inhibitors were introduced
around 2000. There were early concerns regarding a theo-
retic increased risk of cardiovascular side effects, because
it was thought that PGI2 levels could be diminished while
platelet and tissue levels of TX would not be altered. This
hypothesis was supported by a study that demonstrated a de-
crease in urinary metabolites of PGI2, but no reduction in
urinary metabolites of TX in healthy volunteers taking cel-
ecoxib.23 This study did not, however, consider that COX-2
produces prostaglandins such as PGI2 in many tissues,
including the lungs and colon, and the concentration of uri-
nary metabolites is not necessarily a reflection of vascular or
perivascular tissue concentrations. In our study, both COX-
2 inhibition and nonselective COX inhibition resulted in
markedly reduced serum PGI2 levels, as well as decreased
PGI2 and slightly increased TXA2 levels, in the ischemic
myocardium. The decreases in PGI2 tissue levels in the cel-
ecoxib group were more modest than those in the naproxen
group.
The risk of adverse events may be dose dependent. For ex-
ample, the Adenomatous Polyp Celecoxib trial found cele-
coxib to be associated with increased adverse events when
administered at doses greater than those generally prescribed
for arthritic conditions.24 Additionally, in a pooled analysis
examining celecoxib use in about 8000 patients (approxi-
mately 16,000 patient-years of follow up) from recent
randomized controlled clinical trials, the risks of cardiovas-
cular death, myocardial infarction, stroke, heart failure, and
thromboembolism were shown to be dose dependent, with
hazard ratios of 1.1 for a dose of 400 mg daily and 3.1 for
a dose of 400 mg twice a day.25 At dosages recommended
for treatment of osteoarthritis (200 mg once per day), cele-
coxib has not been associated with an increased incidence
of adverse events in any clinical trial to date. On the assump-
tion that swine demonstrate similar dose-dependent effects,
we decided to use relatively high doses of celecoxib and nap-
roxen to create conditions similar to those in the studies in
which cardiac complications were observed.
There are several limitations of this study. First, it was
performed in a porcine model of chronic myocardial ische-
mia. Although in most situations the porcine coronary circu-
lation closely mimics the physiology and pathophysiology
of the human coronary circulation, this may not necessarilyThe Journal of Thoracic and Carbe the case for COX inhibition. Although the experimental
methods in this study have been used extensively in the
past, it is possible that they do not accurately represent all
changes in the swine related to the drug treatment in this
study. For example, the microsphere flow data may have
been influenced by cardiac output. Second, a nondiseased
porcine model was used, as opposed to an elderly, diabetic,
or hypercholesterolemic model. Most patients with arthritic
conditions requiring NSAIDs have some endothelial dys-
function related to preexisting conditions. Third, there
were more animal deaths in the naproxen group than in the
other groups. These animals were not included in any part
of the analysis, and this may introduce a potential survival
bias. Fourth, although we discontinued treatment drugs 24
hours before the final experiment, this period was not suffi-
cient for full washout of the drug, and it is likely that residual
drug was present. We attempted to minimize the acute ef-
fects of COX inhibition in an attempt to examine its long-
term effects on collateral-dependent perfusion. It is likely
that continuing the drugs until the time of the final experi-
ment would have produced different findings, reflecting con-
tinued inhibition of COX or COX-2. Additionally, only
a single high dose of each drug was examined, and different
doses may result in different effects. Finally, not all COX-2
inhibitors display similar specificity for COX-2, and many
have different toxicologic profiles. It is incorrect to assume
that because a given drug in a group is associated with an ad-
verse effect that there is a ‘‘class effect’’ and that all mem-
bers share the effect or share it to the same degree. Drugs
in this group likely function along a spectrum of potential
actions on multiple pathways.
In conclusion, both a selective COX-2 and a non-selective
COX inhibitor altered local and systemic physiology but did
not alter myocardial perfusion relative to the control group.
Although COX inhibition did not lead to reduced blood flow
to the ischemic territory, both nonselective and selective in-
hibition led to lower levels of local vasodilators, decreased
prostaglandin levels, and diminished capillary density and
endothelial cell division. There were, however, some impor-
tant differences between the effects of naproxen and cele-
coxib, such as their effects on hemodynamics, oxidative
stress, apoptosis, and alteration of microvascular responses.
The effects of selective and nonselective COX inhibition
appear to be very complex, but on the basis of this work it
appears that collateral-dependent myocardial blood flow is
not reduced with COX inhibition in this model.
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Dr Y. JosephWoo (Philadelphia, Pa). That is a very impressive
amount of work. The microvascular perfusion in the NSAID group
was higher than the other groups, correct?
Dr Robich. Yes, the perfusion in the myocardium, the blood
flow, was increased.
Dr Woo. So how do you explain that in light of all of the other
findings?
Dr Robich. One thing that we didn’t look at was some of the
more upstream arterials that are supplying blood flow. So we are
not sure whether that is playing a part in this as well.
Dr Woo. Did you catheterize the animals?
Dr Robich. They did get catheterized, correct. There were no
differences in Rentrop scores or in myocardial blush grading. So
from an angiographic standpoint, there wasn’t any increase in large,
large vessels.
Dr Woo. So potentially something smaller than what is angio-
graphically visible, but larger than microvascular?
Dr Robich. Exactly, exactly.
Dr John S. Ikonomidis (Charleston, SC). Can you comment on
how you validated the doses that you used in this study?
Dr Robich.Well, basically the way we approached this is those
dosing levels would be standard starting doses in human patients.
The swine weigh about half as much, and so this would represent
a higher dose of drug to the swine. Most of the clinical trials
have demonstrated this increase in adverse events at higher doses
of the drugs, so we wanted to use a higher dose.
Dr Ikonomidis. Have you generated a specific pharmacokinetic
profile for these drugs in swine?
Dr Robich. No, we have not.
Dr Michael E. Jessen (Dallas, Tex). Did you have any animals
die during the course of the experiment?
Dr Robich.We did. We had 1 die in the control group, 3 in the
naproxen group, and 1 in the celecoxib group.
Dr Jessen.Did you necropsy them to find what the causes were?
Dr Robich.Yes, we did a gross necropsy of each animal, Unfor-
tunately, a lot of times animals die in this experiment and other ex-
periments from, we presume, a ventricular arrhythmia, because
there is no real gross or histologic finding to suggest why they
died. Two animals in the naproxen group and 1 in the celecoxib
group showed symptoms that were similar to heart failure. They
were short of breath and breathing tachypneically.
Dr Jessen.How far down the line from the placement of the con-
strictor did this occur?
Dr Robich. All the animals that died in this experiment died
somewhere around the third or fourth week. So they were out
a fair bit. Now, we analyzed that, and obviously in a very small
study like this that didn’t reach statistical significance. But we
did have some deaths.gery c November 2010
